Abstract
Activation of the ATP-gated P2X7 receptor (P2X7R), implicated in numerous diseases of the brain, can trigger diverse responses such as the release of pro-inflammatory cytokines, modulation of neurotransmission, cell proliferation or cell death. However, despite the known species-specific differences in its pharmacological properties, to date, most functional studies on P2X7R responses have been analyzed in cells from rodents or immortalised cell lines. To assess the endogenous and functional expression of P2X7Rs in human astrocytes, we differentiated human-induced pluripotent stem cells (hiPSCs) into GFAP and S100 β-expressing astrocytes. Immunostaining revealed prominent punctate P2X7R staining. P2X7R protein expression was also confirmed by Western blot. Importantly, stimulation with the potent non-selective P2X7R agonist 2′,3′-O-(benzoyl-4-benzoyl)-adenosine 5′- triphosphate (BzATP) or endogenous agonist ATP induced robust calcium rises in hiPSC-derived astrocytes which were blocked by the selective P2X7R antagonists AFC-5128 or JNJ-47965567. Our findings provide evidence for the functional expression of P2X7Rs in hiPSC-derived astrocytes and support their in vitro utility in investigating the role of the P2X7R and drug screening in disorders of the central nervous system (CNS).
Similar content being viewed by others
Introduction
The P2X7 receptor (P2X7R) belongs to the cationic P2X receptor family and plays a pivotal role in ATP-mediated signal transmission in the brain [1]. The downstream consequences of P2X7R signaling are dependent on its cellular location and various non-cell autonomous effects have been reported. P2X7R activation on microglia leads to the release of pro-inflammatory mediators (e.g. interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α)), triggering neuroinflammation [2]. In contrast, the presence of P2X7Rs on other brain cell types such as neurons and astrocytes is less certain. Activation of P2X7Rs on astrocytes has been reported to evoke glutamate release leading to potential excitotoxic effects [3]. Astrocyte-mediated P2X7R responses may, however, also be important for the release of pro-inflammatory cytokines [4]. However, other studies have failed to detect P2X7Rs on this cell type [5, 6].
Due to its distinct characteristics, including its relatively low affinity for ATP and its prominent role in driving inflammatory processes, P2X7R has attracted considerable interest as a potential target for various neurological conditions including neurodegenerative and psychiatric diseases, and epilepsy. P2X7R protein expression has been found to be up-regulated in the brain of patients with different brain diseases and P2X7R antagonism has shown benefits in multiple animal models (e.g. epilepsy, schizophrenia, depression) [7].
Despite the 80% sequence homology between human and murine P2X7Rs, differences in receptor sensitivity towards various ligands between humans and rodents have been described. This includes the non-selective agonist 2′, 3′-O-(benzoyl-4-benzoyl)-adenosine 5′- triphosphate (BzATP) [8], the potent P2X7Rs antagonist KN-62 (1‐[N,O‐bis(5‐isoquinolinesulphonyl)‐N‐methyl‐L‐tyrosyl]‐4‐phenylpiperazine) [9], and GW791343, a negative modulator at human P2X7Rs, but a positive modulator at rat P2X7Rs [10]. Thus, P2X7Rs exhibit remarkable species-specific differences in the pharmacological properties, demonstrating the need for the investigation of P2X7Rs in human brain-relevant models. Resected human primary brain tissue is very scarce and often shows alterations associated with pathology. Induced pluripotent stem cell (iPSC)-derived human neurons and glia have demonstrated great potential for the investigation of human neuronal development in vitro, pharmacological screening and assessing phenotypic alterations in patient-specific iPSC-derived neural cells [11].
In rodent brain, although P2X7Rs are preferentially localized on microglia, they are also expressed on other cell types (e.g. oligodendrocytes and most likely astrocytes and neurons). Importantly, P2X7R-mediated effects via astrocytes have been suggested to contribute to disease progression in several brain diseases [12]. To date, only few studies have, however, addressed the functional expression of the P2X7R in human primary astrocytes [13, 14]. Here, we demonstrate the expression of P2X7Rs in hiPSC-derived astrocytes, thereby establishing a model for the investigation of functional P2X7Rs in a human system.
Methods
Culture and differentiation of hiPSCs
hiPSC line HPSI0114i-eipl_1 (ECACC 77,650,081; Culture Collections, Public Health England, UK) was maintained under feeder-free conditions on vitronectin (STEMCELL Technologies, British Columbia, Canada)-coated 6-well plates in E8 medium (Thermo Fisher Scientific, Massachusetts, U.S.A). hiPSCs were dissociated by using 0.5 mM EDTA for 2 min at 37 °C, and reseeded at the density of 1 × 104 cells/cm2. For neural induction of hiPSCs, approximately 24 h after splitting, culture medium was switched to Gibco PSC Neural Induction Medium (Thermo Fisher Scientific, Massachusetts, U.S.A). At day 10 of neural induction, primitive NSCs (pNSCs) were dissociated with Accutase (Thermo Fisher Scientific, Massachusetts, U.S.A) and plated on Geltrex-coated dishes at a density of 1 × 105 cells/cm2 in NSC expansion medium containing 50% Neurobasal medium, 50% Advanced DMEM/F12, and 1% neural induction supplement (Thermo Fisher Scientific, Massachusetts, U.S.A). pNSCs were passaged on the 4th day at a 1:3 split ratio to derive NSCs and cells at passage 4 were used for the differentiation of glia. For astrocyte differentiation, pNSCs were plated onto Geltrex-coated coverslips at a density of 5 × 104 cells/cm2 in an astrocyte differentiation medium (DMEM supplemented with 1% fetal bovine serum, 1% sodium pyruvate, 1% non-essential amino acids, 0.5% G-5 supplement (all from Thermo Fisher Scientific, Massachusetts, U.S.A)) for 5 days. Astrocytes were passaged at a split ratio of 1:2 and used for experimentation at passage 7–10.
Immunocytochemistry
Astrocytes cultured on coverslips were fixed with 4% paraformaldehyde or a combination of acetic acid (6.71%) and ethanol (62.5%) for 15 min. After 3 washes in phosphate buffered saline, cells were permeabilised with 0.1% Triton for 20 min and blocked in 1% BSA for 30 min. Cells were incubated at 4 °C overnight in primary antibody diluted in 1% BSA. Cells were then incubated in secondary antibody diluted in 1% BSA for 1 h at room temperature. Primary antibodies: mouse anti-GFAP (Merck, Missouri, United States, Cat. Nr. G6171, dilution 1:200), mouse anti-S100β (Abcam, Cambridge, UK, Cat. Nr. Ab52642, dilution 1:200), rabbit anti-P2X7R (Alomone Labs, Jerusalem, Israel, Cat. Nr. APR-004, dilution 1:200). The respective secondary antibodies were conjugated to Alexa Fluor 488 or 594 (Thermo Fisher Scientific, Massachusetts, U.S.A). Nuclei were counterstained with Hoechst (Merck, Missouri, United States).
Drug application
Stock solutions of BzATP (Alomone Labs, Jerusalem, Israel), ATP (Merck, Missouri, United States), AFC-5128 (provided by Affectis Pharmaceuticals AG, Dortmund, Germany) [15] and JNJ-47,965,567 (Alomone Labs, Jerusalem, Israel) were diluted in HEPES-buffered extracellular solution. Drug solutions were delivered to recorded cells by a valve-controlled fast multibarrel superfusion system with a common outlet ~ 350 μm in diameter (Automate Scientific, California, U.S.A) with a final concentration: BzATP, ATP (300 µM), AFC-5128 (30 nM), JNJ-47965567 (100 nM).
Calcium imaging
Cells were loaded with Cal-520 (AAT Bioquest, California, U.S.A) by incubation with the acetoxymethyl (AM) ester form of the dye at a final concentration of 2 µM in culture media without serum. Dyes were prepared as 5 mM stock solution in DMSO and kept frozen at -20 °C until diluted. After 45 min, cells were washed several times with dye-free HEPES-buffered saline solution and transferred to an imaging chamber on a microscope (Zeiss Axio Examiner, Jena, Germany) equipped with a Zeiss 40x water immersion objective. Zen Blue imaging software (Carl Zeiss, Jena, Germany) was used for hardware control and image acquisition. Image analysis was performed using ImageJ (NIH, Maryland, U.S.A). All imaging experiments were performed at 34 °C in a low divalent cation-containing bath solution with the composition (in mM): 135 NaCl, 3 KCl, 0.5 CaCl2, 0.1 MgCl2, 10 HEPES and 10 glucose (pH 7.2; osmolality 290–300 mmol/kg). Images were acquired at 4 Hz. Background fluorescence was measured from the cell-free area outside the soma of interest in each frame of every time series. Region of interests were drawn around the soma and baseline fluorescence intensity (F0) was determined by averaging 24 frames preceding the cell’s exposure to BzATP or ATP and the time course of normalized fractional dye fluorescence [ΔF/F0] was obtained, where ΔF equals F(t) - F0.
Western blot
hiPSC-derived astrocytes were homogenized in ice-cold extraction buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1 µM okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA, protease inhibitors (Complete, Roche, Cat. No 11,697,498,001)), electrophoresed on 8–10% sodium dodecyl sulphate (SDS)-polyacrylamide gel, transferred to nitrocellulose blotting membrane (Amersham Protran 0.45 μm, GE Healthcare Life Sciences) and blocked in TBS-T (150 mM NaCl, 20 mM Tris–HCl, pH 7.5, 0.1% Tween 20) supplemented with 5% non-fat dry milk. Membranes were incubated overnight at 4ºC with the rabbit anti-P2X7R antibody (Alomone Labs, Cat. Nr. APR-004, Jerusalem, Israel). On the next day, following washing with TBS-T, membranes were incubated with secondary HRP-conjugated IgG (Jackson Immuno Research, Plymouth, PA, U.S.A) and protein bands visualized using chemiluminescence. Gel bands were captured using a Fujifilm LAS-4000 imaging system (Fujifilm, Tokyo, Japan). GFAP (Merck, Missouri, U.S.A) was used as loading control. Hippocampal tissue from 8 week-old male P2X7R knock-out (KO) mice (C56BL/6 N-P2rx7tm1d(EUKOMM)wtsi) and corresponding wild-type (wt) mice (C67/Bl6 OlaHsd) was used as negative and positive control to test for P2X7R antibody specificity [16]. All animal experiments were performed in accordance with the principles of the European Communities Council Directive (2010/63/EU) and procedures were reviewed and approved by the Research Ethics Committee of the Royal College of Surgeons in Ireland (REC 1322) and Health Products Regulatory Authority (HPRA) (AE19127/P038).
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using the Mann-Whitney U test. P < 0.05 was considered statistically significant. All statistical analyses was performed with GraphPad Prism 9 software (GraphPad Software, San Diego, CA, U.S.A).
Results
Expression of P2X7Rs in hiPSC-derived astrocytes
hiPSC-derived astrocytes, differentiated for 4 weeks in vitro and positive for the astrocyte marker S100β, showed a flat morphology (Fig. 1a-d). Astrocytes exhibited a weak signal for Cal-520 fluorescence indicating low resting [Ca2+]i with occasional spontaneous asynchronous [Ca2+]i fluctuations (Fig. 1f). Immunohistochemistry at 4 weeks in vitro showed a punctate staining pattern for P2X7R in GFAP-positive cells demonstrating the expression of P2X7Rs (Fig. 1g-i), which was further confirmed by Western blotting (Fig. 1l). Thus, astrocyte identity of the cells differentiated from pNSCs was validated by immunostaining for S100β which is a Ca2+-binding protein abundantly expressed in astrocytes, and GFAP which is a major inter-filamentous protein of mature astrocytes. Immunocytochemical analysis also revealed that 100% of Hoechst-positive nuclei were also GFAP-positive indicating a highly pure population of astrocytes.
ATP evokes AFC-5128 or JNJ-47965567-sensitive Ca2+transients in iPSC-derived astrocytes
Functional expression of P2X7Rs was assessed by monitoring changes in [Ca2+]i using the calcium-sensitive fluorescent reporter Cal-520. Pulse ejection of BzATP (300 µM) for 5 s evoked synchronous increase in [Ca2+]i persisting for a few seconds following agonist wash-out (Fig. 2a). In contrast, pre-incubation of astrocytes with the P2X7R antagonist AFC-5128 (30 nM), followed by co-application of BzATP with AFC-5128, reduced BzATP-mediated [Ca2+]i responses (Fig. 2a,b). The area under ΔF/F0 curve (AUC) upon BzATP application was reduced when stimulated in the presence of AFC-5128 (Fig. 2c). Similar results were also evident when the peak amplitude of individual ΔF/F0 traces were compared (Fig. 2d,e). Likewise, AFC-5128 also reduced ATP-induced [Ca2+]i rises, AUC of ΔF/F0 traces and peak amplitude (Fig. 2f-i). Similar to AFC-5128, the P2X7R antagonist JNJ-47965597 (100 nM) reduced BzATP and ATP-evoked [Ca2+]i signals (Fig. 2h, i), AUC and peak amplitude of individual ΔF/F0 traces (Fig. 2j-r). The averaged time course of BzATP or ATP-evoked [Ca]i shown in Fig. 2f, j and o shows a biphasic response probably caused by Ca2+-induced Ca2+ release. The attenuation of Ca2+ response in the presence of JNJ-47965597 for the period of ATP application is also shown in the magnified view in the inset (Fig. 2o). Since astrocytes were not mitotically inhibited, astrocytes at different maturation stages could account for the slightly different kinetics observed in response to the agonist application.
Discussion
Here, we show that astrocytes respond by [Ca2+]i increase upon ATP and BzATP which was blocked via the selective P2X7R antagonists AFC-5128 or JNJ-47965567. Therefore, the present findings support the use of hiPSC-derived astrocytes as a human brain-relevant in vitro model for studying ATPergic signaling, disease mechanisms and drug screening.
To date, only two studies have reported the presence of P2rx7 mRNA in cultured human adult and fetal brain tissue [14, 17]. Studies investigating a causative role of P2X7R in brain diseases have, however, relied heavily on experimental animal models. This raises potential problems with translation since the P2X7R exhibits remarkable species-specific differences in their pharmacological properties to drugs such as AFC-5128 [15]. hiPSC-derived glia have been widely accepted as human brain-relevant in vitro cellular models to investigate phenotypic alterations in neurological diseases [11, 18]. Thus, to advance findings from pre-clinical experimentation into the clinical setting, the development of human-derived cellular models for targeted drug screening, such as that for the P2X7R in this study, would serve an invaluable tool to bridge the gap between translational animal models and human neurological diseases.
The present study provides strong evidence that hiPSC-derived astrocytes express functional P2X7Rs. This is based on imaging evidence and the fact that P2X7R antagonists selectively blocked calcium entry. Our results therefore agree with studies showing functional P2X7R on astrocytes in mice, rats and humans [19], but are in contrast to other studies unable to detect P2X7R on rat and human astrocytes [5, 6] including work by our own group in mice [20].
It is important to keep in mind that our studies are carried out under in vitro conditions and whether P2X7Rs are expressed in vivo in human astrocytes requires further investigation (e.g. patch clamp in human brain slices). P2X7Rs have been shown to be upregulated in human reactive astrocytes [17]. We did not detect discernable changes in morphology of astrocytes in culture over time, but did not assess if the culture conditions lead to neuroinflammation and the generation of reactive astrocytes. BzATP-evoked responses should be interpreted with caution because BzATP is a non-specific agonist at purinergic receptors and agonist activity at non-P2X7Rs has been documented. Importantly, suggesting ATP- and BzATP-mediated responses are mainly mediated via P2X7Rs, the specific P2X7R antagonists AFC-5128 or JNJ-47965567 suppressed the observed calcium increases. Finally, our results should be studied in additional iPSC lines, from healthy individuals and patients carrying potential pathogenic gene variants.
In conclusion, here we demonstrate the expression of functional P2X7Rs on hiPSCs-derived astrocytes and provide the proof-of-concept that hiPSCs represent a valid model to study P2X7Rs signaling in human cellular models.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Kopp R, Krautloher A, Ramirez-Fernandez A, Nicke A (2019) P2X7 Interactions and Signaling - Making Head or Tail of It. Front Mol Neurosci 12:183. https://doi.org/10.3389/fnmol.2019.00183
Solle M, Labasi J, Perregaux DG, Stam E et al (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276(1):125–132. https://doi.org/10.1074/jbc.M006781200
Duan S, Anderson CM, Keung EC, Chen Y et al (2003) P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 23(4):1320–1328. https://doi.org/10.1523/JNEUROSCI.23-04-01320.2003
Choi SS, Lee HJ, Lim I, Satoh J et al (2014) Human astrocytes: secretome profiles of cytokines and chemokines. PLoS ONE 9(4):e92325. https://doi.org/10.1371/journal.pone.0092325
Jabs R, Matthias K, Grote A, Grauer M et al (2007) Lack of P2X receptor mediated currents in astrocytes and GluR type glial cells of the hippocampal CA1 region. Glia 55(16):1648–1655. https://doi.org/10.1002/glia.20580
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A et al (2018) Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife 7. https://doi.org/10.7554/eLife.36217
Andrejew R, Oliveira-Giacomelli A, Ribeiro DE, Glaser T et al (2020) The P2X7 Receptor: Central Hub of Brain Diseases. Front Mol Neurosci 13:124. https://doi.org/10.3389/fnmol.2020.00124
Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157(7):1203–1214. https://doi.org/10.1111/j.1476-5381.2009.00233.x
Humphreys BD, Dubyak GR (1998) Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 64(2):265–273. https://doi.org/10.1002/jlb.64.2.265
Michel AD, Chambers LJ, Walter DS (2008) Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol 153(4):737–750. https://doi.org/10.1038/sj.bjp.0707625
Rowe RG, Daley GQ (2019) Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet 20(7):377–388. https://doi.org/10.1038/s41576-019-0100-z
Beltran-Lobo P, Reid MJ, Jimenez-Sanchez M, Verkhratsky A et al (2023) Astrocyte adaptation in Alzheimer’s disease: a focus on astrocytic P2X7R. Essays Biochem 67(1):119–130. https://doi.org/10.1042/EBC20220079
Lovelace MD, Gu BJ, Eamegdool SS, Weible MW 2nd, et al (2015) P2X7 receptors mediate innate phagocytosis by human neural precursor cells and neuroblasts. Stem Cells 33(2):526–541. https://doi.org/10.1002/stem.1864
Hashioka S, Wang YF, Little JP, Choi HB et al (2014) Purinergic responses of calcium-dependent signaling pathways in cultured adult human astrocytes. BMC Neurosci 15:18. https://doi.org/10.1186/1471-2202-15-18
Fischer W, Franke H, Krugel U, Muller H et al (2016) Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models. PLoS ONE 11(6):e0156468. https://doi.org/10.1371/journal.pone.0156468
Beamer E, Morgan J, Alves M, Menendez Mendez A et al (2022) Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice. Br J Pharmacol 179(12):2986–3006. https://doi.org/10.1111/bph.15785
Narcisse L, Scemes E, Zhao Y, Lee SC et al (2005) The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 49(2):245–258. https://doi.org/10.1002/glia.20110
Avior Y, Sagi I, Benvenisty N (2016) Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 17(3):170–182. https://doi.org/10.1038/nrm.2015.27
Zhao YF, Tang Y, Illes P (2021) Astrocytic and Oligodendrocytic P2X7 Receptors Determine Neuronal Functions in the CNS. Front Mol Neurosci 14:641570. https://doi.org/10.3389/fnmol.2021.641570
Morgan J, Alves M, Conte G, Menendez-Mendez A et al (2020) Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse. Neurosci Bull 36(11):1242–1258. https://doi.org/10.1007/s12264-020-00573-9
Funding
This research was supported by funding from Science Foundation Ireland (17/CDA/4708 and 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners), from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (No. 844956, 796600, 846810) and from the Irish Research Council (Government of Ireland Postdoctoral Fellowship Programme, GOIPD/2020/865 and GOIPD/2020/806).
Open Access funding provided by the IReL Consortium
Author information
Authors and Affiliations
Contributions
Conceptualization, J.K. and T.E.; methodology, J.K., L.D.G., M.A., A.M.M., T.E.; formal analysis, J.K.; investigation, J.K.; resources, T.E., O.W., K.D., M.H., D.H., J.H.M.P.; writing—original draft preparation, J.K., T.E.; writing—review and editing, J.K., O.W., T.E., D.H., J.H.M.P.; supervision, T.E.; project administration, T.E.; funding acquisition, J.K., T.E., D.H. and J.H.M.P. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The human iPSC line was obtained from Culture Collections, Public Health England, UK. Consent was obtained from the donor, by the Sanger institute that reprogrammed the fibroblasts into iPSCs and the line was distributed and used under the terms of an MTA from culture collections and RCSI.
Consent for publication
Not applicable.
Competing interests
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. K.D. and M.H. are stakeholders in Lead Discovery Center GmbH and Affectis Pharmaceuticals respectively but had no influence in the study design.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kesavan, J., Watters, O., de Diego-Garcia, L. et al. Functional expression of the ATP-gated P2X7 receptor in human iPSC-derived astrocytes. Purinergic Signalling (2023). https://doi.org/10.1007/s11302-023-09957-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11302-023-09957-8